To promote the exploration of more effective and safer anti-MDR therapy options, Creative Biolabs now provides CRO services for the discovery of antibodies and peptides targeting MDR bacteria, including Pseudomonas and Streptococcus.
New York, United States - November 26, 2021 /MarketersMEDIA/ —
Multidrug-resistant bacteria (MDR bacteria) are widely acknowledged as one of the most serious public health issues today. Antimicrobial resistance is “one of the greatest threats to human health worldwide,” according to the Infectious Diseases Society of America (IDSA). It is affecting many parts of the medical field and threatens to reduce the yield of numerous achievements, including cancer treatment, transplantation, and surgeries.
While it is urgent to discover effective anti-bacteria treatments, antibodies and peptides offer new prospects for the development of treatment strategies to tackle certain antibiotic-tolerant infections. With an established high-throughput Anti-Bacteria Biomolecular Discovery System, Creative Biolabs is proficient in CRO services for the discovery of antibodies and peptides targeting MDR bacteria, including but not limited to Pseudomonas, Streptococcus, Enterococcus, Staphylococcus, and Mycobacterium.
· Antibody and Peptide Discovery Targeting Pseudomonas
The expert team at Creative Biolabs has updated anti-Pseudomonas antibody and peptide development services to advance related research. The experienced scientists consider it highly promising to utilize biofilms, as well as type a and b flagellins of Pseudomonas, as targets for antibodies and peptides development, and will be a reliable partner to power up clients’ programs.
“Pseudomonas aeruginosa is becoming more well recognized as a clinically important pathogen. But its limited antibiotic susceptibility is one of its most problematic properties. Thus it is essential to find new effective therapeutic approaches,” as introduced by a senior scientist at Creative Biolabs, “so we are dedicated to combining a range of advanced technologies, like hybridoma technology, phage display, and peptide array, to offer comprehensive custom services on anti-Pseudomonas antibody or peptide development research.”
· Antibody and Peptide Discovery Targeting Streptococcus
Streptococcal infections can cause many disorders, including strep throat, pneumonia, and wound, skin, heart valve, and bloodstream infections. To advance new drug development, Creative Biolabs has accumulated extensive experience in the discovery of novel antibodies and peptides targeting Streptococcus.
The services will facilitate research on Cα and R4 proteins, surface immunogenic protein (SIP) and pneumococcal surface protein A (PspA) as Streptococcus targets for antibody discovery, and potential antimicrobial peptides (AMPs), such as hybrid peptides of natural peptides indolicidin and ranalexin, and the chemically synthesized peptide M-Brucin.
More information about antibody/peptide discovery services for bacterial diseases at Creative Biolabs can be found at https://www.creative-biolabs.com/antinfect/.
About Creative Biolabs
As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technology to support functional biomolecules development for infectious diseases. The service portfolio is comprised of anti-infective antibody and peptide discovery, and small molecule drug discovery.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/antinfect/
Source: MarketersMEDIA
Release ID: 89054460
